RAPHAS
Korea - SeoulBiotechnology
Focus: RAPHAS is a Korean biotechnology company specializing in biodegradable microneedle drug delivery patch technology, currently generating 100% revenue from a single approved infectious disease product.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Open Jobs
5
Should You Work at RAPHAS?
AI assessmentRAPHAS is a high-risk, high-opportunity micro-cap biotech suitable only for candidates seeking early-stage exposure and comfortable with platform-stage company uncertainty.
Why Work Here
- Opportunity to work on innovative drug delivery platform (biodegradable microneedles) with potential to expand beyond single-product revenue model
- Early-stage pipeline with Phase 1 allergy program signals diversification away from XERAVA dependency
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$788K Part DStable
Peak11.2yr
RAPHAS' only approved product and sole revenue driver; represents 100% of company revenue and provides patent protection through 2037.
Help build intelligence for RAPHAS
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.